STAT3 and colorectal carcinoma: Besides, the level of activated p-Stat3 increased in 45 primary CRC samples compared with adjacent normal mucosae has been reported.6 Therefore, directly inhibiting Stat3 might be a promising novel approach for CRC therapy.